Skip to main content
    C

    Cytosorbents Crp (CTSO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.52
    -0.33 (-6.80%)

    Market Cap: $15.28M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Cytosorbents Crp (CTSO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Cytosorbents Crp (CTSO) has a market cap of $15.28M and an enterprise value of $28.11M. It kept -48.94% of revenue as net income over the last 12 months. Its net debt of $12.83M equals 83.94% of its market cap.

    Total Valuation

    Enterprise value is 83.94% above the market cap, as debt exceeds cash.

    Market Cap$15.28M
    Enterprise Value$28.11M
    Latest price (Nov 17, 2026)$4.52

    Key Dates

    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.11% in the quarter ended Jun 30, 2026 and grew 7.54% a year over 2 years.

    Shares Outstanding3.14M
    Shares Change (YoY)+0.32%
    Shares Change (QoQ)+0.11%
    Share Count Growth (2Y CAGR)+7.54%

    Valuation Ratios

    The price to sales ratio is 0.4x. Its year-end P/S ranged from 21.5x to 291.1x from 2016 to 2025.

    P/S Ratio0.4x
    Forward P/S0.4x

    Price Statistics

    The stock is down 65.76% over 52 weeks and trades 5.64% below its 50-day average.

    Beta (1Y)1.19
    52-Week Change-65.76%
    1-Month Change-8.87%
    3-Month Change-36.52%
    6-Month Change-52.17%
    5-Year Change-96.15%
    10-Year Change-96.15%
    Total Return (1Y)-65.76%
    Total Return (3Y CAGR)-41.68%
    Total Return (5Y CAGR)-47.49%
    Return vs SPY (1Y)-75.20%
    Max Drawdown (1Y)-81.72%
    Max Drawdown (3Y)-91.68%
    Sharpe Ratio (1Y)-1.04
    Correlation with SPY (1Y)0.17
    50-Day Average$4.79
    200-Day Average$8.98
    52-Week Range$2.84 to $17.00
    RSI (14 Days)45.8
    Average Volume (20 Days)29.10K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.66x current liabilities.

    Current Ratio0.66x
    Quick Ratio0.50x

    Returns and Efficiency

    Return on invested capital is -74.25% over the last 12 months, against a 5-year average of -69.62%.

    Return on Assets (ROA)-47.98%
    Return on Invested Capital (ROIC)-74.25%
    Return on Capital Employed (ROCE)-111.20%
    ROA (5Y Average)-39.37%
    ROIC (5Y Average)-69.62%
    Asset Turnover0.87x
    Inventory Turnover2.59x
    Receivables Turnover5.34x
    Cash Conversion Cycle121 days

    Scores

    CTSO has an Altman Z-Score of -12.28, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-12.28
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $37.22M over the last 12 months is up 3.07% from the 12 months before.

    Revenue$37.22M
    Revenue Growth (YoY)+3.07%
    Gross Profit$26.65M
    Operating Income-$12.93M
    Pretax Income-$18.61M
    Net Income-$18.21M
    EBIT-$15.50M
    Reported EPS (TTM)-$0.82

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$4.41M
    Total Debt$17.24M
    Net Debt$12.83M
    Net Debt Per Share$4.08
    Working Capital-$8.29M
    Shareholder Equity-$751.00K
    Tangible Book Value-$3.62M
    Total Assets$37.96M
    Total Liabilities$38.71M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $150.00K of capital spending, operating cash flow left -$9.30M of free cash flow.

    Operating Cash Flow-$9.15M
    Capital Expenditures$150.00K
    Free Cash Flow-$9.30M
    FCF Per Share-$2.95
    Depreciation and Amortization$2.55M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -34.74%, against a 5-year average of -66.47%.

    Gross Margin71.61%
    Operating Margin-34.74%
    Pretax Margin-50.02%
    Net Margin-48.94%
    EBIT Margin-41.64%
    FCF Margin-24.98%
    Gross Margin (5Y Average)69.24%
    Operating Margin (5Y Average)-66.47%
    Net Margin (5Y Average)-65.18%

    Growth

    Revenue grew 2.23% a year over 3 years.

    Revenue Growth (3Y CAGR)+2.23%
    Revenue Growth (5Y CAGR)-2.00%
    Book Value Per Share Growth (2Y CAGR)-57.72%
    Tangible Book Per Share Growth (2Y CAGR)-71.53%

    Revenue and profit by year

    Dividends and Yields

    CTSO does not pay a dividend. Its free cash flow yield is -65.50%.

    FCF Yield-65.50%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-20 reverse split on Sep 8, 2026.

    Last Split DateSep 8, 2026
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 10 similar companies, CTSO has the 9th highest P/S and the 4th highest ROIC.

    P/S Ratio0.4x vs 1.7x median
    ROIC-74.25% vs -189.69% median
    Revenue Growth (Trailing 4 Quarters, YoY)+3.07% vs +11.65% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.16% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.16%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CTSO

    What is CTSO's market cap?

    Cytosorbents Crp has a market cap of $15.28M. Its enterprise value, which adds debt and subtracts cash, is $28.11M.

    How many shares of CTSO are outstanding?

    Cytosorbents Crp has 3.14M shares outstanding. The count is up 0.32% from a year earlier.

    Does CTSO pay a dividend?

    No. Cytosorbents Crp does not pay a dividend.

    How much debt does CTSO have?

    Cytosorbents Crp has $17.24M of total debt and $4.41M of cash and equivalents, a net debt position of $12.83M.